| Issue Date | Title | Author(s) |
| Jun-2023 | Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer | Lei, Huizi; Ling, Yun; Yuan, Pei; Yan, Xieqiao; Wang, Lin; Shi, Yanxia; Yao, Xin; Luo, Hong; Shi, Benkang; Liu, Jiyan; He, Zhisong; Yu, Guohua; Han, Weiqing; Hu, Changlu; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Fang, Jianmin; Guo, Jun; Sheng, Xinan; Zhou, Aiping; Ying, Jianming |
| 25-Oct-2022 | Bifunctional anti-PD-L1/TGF-beta RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial | Liu, Dan; Zhou, Jun; Wang, Yongsheng; Li, Mingjun; Jiang, Haiping; Liu, Yunpeng; Yin, Xianli; Ge, Minghua; Xiang, Xiaojun; Ying, Jieer; Huang, Jian; Zhang, Yan-qiao; Cheng, Ying; Huang, Zhigang; Yuan, Xianglin; Han, Weiqing; Yan, Dong; Wang, Xinshuai; Liu, Pan; Wang, Linna; Zhang, Xiaojing; Luo, Suxia; Liu, Tianshu; Shen, Lin |
| 2016 | Chronic Exercise Training Improved Aortic Endothelial and Mitochondrial Function via an AMPK alpha 2-Dependent Manner | Chen, Xiaohui; An, Xiangbo; Chen, Dongrui; Ye, Maoqing; Shen, Weili; Han, Weiqing; Zhang, Youyi; Gao, Pingjin |
| May-2021 | Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma | Liu, Dan; Ma, Chunguang; Lu, Ping; Gong, Jifang; Ye, Dingwei; Wang, Siyang; Peng, Peijian; Bai, Yuxian; Song, Yuqin; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Ba, Yi; Chen, Li; Pan, Jianji; Li, Qi; Zhang, Liling; Gu, Shanzhi; Yin, Xianli; Cao, Bangwei; Han, Weiqing; Dong, Haiying; Guo, Jianming; Zhang, Huilai; Su, Hang; Jiang, Yongsheng; Ouyang, Weiwei; Ma, Lulin; Sun, Yan; Zhang, Feng; Lv, Jun; Guo, Yabing; Xu, Chongyuan; Qi, Junyuan; Wang, Li; Wang, Xiang; Liu, Zhen; Shen, Lin |
| 20-Apr-2024 | Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials | Sheng, Xinan; Wang, Lin; He, Zhisong; Shi, Yanxia; Luo, Hong; Han, Weiqing; Yao, Xin; Shi, Benkang; Liu, Jiyan; Hu, Changlu; Liu, Ziling; Guo, Hongqian; Yu, Guohua; Ji, Zhigang; Ying, Jianming; Ling, Yun; Yu, Shiying; Hu, Yi; Guo, Jianming; Fang, Jianmin; Zhou, Aiping; Guo, Jun |
| Apr-2022 | Enzalutamide in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study | Pu, Yeong-Shiau; Ahn, Hanjong; Han, Weiqing; Huang, Shu-Pin; Wu, Hsi-Chin; Ma, Lulin; Yamada, Shunsuke; Suga, Kazutaka; Xie, Li-Ping |
| Aug-2020 | GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial | Shen, Lin; Gong, Jifang; Song, Yuqin; Ye, Dingwei; Lu, Zhihao; Wang, Siyang; Peng, Peijian; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Bai, Yuxian; Pan, Jianji; Ma, Chunguang; Chen, Li; Ma, Yi; Li, Qi; Lu, Ping; Zhang, Lingli; Yin, Xianli; Gu, Shanzhi; Zhang, Huilai; Su, Hang; Jiang, Yongsheng; Cao, Bangwei; Han, Weiqing; Sun, Yan; Zhang, Feng; Ouyang, Weiwei; Dong, Haiying; Guo, Jianming; Guo, Yabing; Xu, Chongyuan; Qi, Junyuan; Wang, Li; Lv, Jun; Wang, Xiang; Chen, Chris; Li, Jing; Zheng, Yong; Jin, Ge; Yang, Yining; Zhao, Guodong; Yang, Fan; Xu, Kehui; Liang, Xiangying; Pan, Zhaoyang; Meng, Haijin |
| 1-Jan-2021 | Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma | Sheng, Xinan; Yan, Xieqiao; Wang, Lin; Shi, Yanxia; Yao, Xin; Luo, Hong; Shi, Benkang; Liu, Jiyan; He, Zhisong; Yu, Guohua; Ying, Jianming; Han, Weiqing; Hu, Changlu; Ling, Yun; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Fang, Jianmin; Zhou, Aiping; Guo, Jun |
| 20-May-2021 | An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009). | Sheng, Xinan; He, Zhisong; Han, Weiqing; Zhou, Ai-Ping; Luo, Hong; Shi, Yanxia; Hu, Changlu; Liu, Ziling; Guo, Hongqian; Yao, Xin; Shi, Benkang; Liu, Jiyan; Ji, Zhigang; Guo, Jianming; Hu, Yi; Yu, Shi Ying; Yu, Guohua; Ying, Jianming; Fang, Jianmin; Guo, Jun |
| 2019 | A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. | Sheng, Xinan; Zhou, Ai-Ping; Yao, Xin; Shi, Yanxia; Luo, Hong; Shi, Benkang; Liu, Jiyan; Yu, Guohua; He, Zhisong; Hu, Changlu; Han, Weiqing; Fang, Jianmin; Guo, Jun |
| 1-Jun-2022 | RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. | Sheng, Xinan; He, Zhisong; Shi, Yanxia; Luo, Hong; Han, Weiqing; Yao, Xin; Shi, Benkang; Liu, Jiyan; Hu, Changlu; Liu, Ziling; Guo, Hongqian; Yu, Guohua; Ji, Zhigang; Yu, Shiying; Hu, Yi; Guo, Jianming; Ying, Jianming; Fang, Jianmin; Zhou, Aiping; Guo, Jun |
